Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Palo Verde Hematology Oncology
Glendale, Arizona, United States
- Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
- California Cancer Associates for Research and Excellence
Fresno, California, United States
- Mayo Clinic Jacksonville
Jacksonville, Florida, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- the University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2013
- Primary completion
- 30 Jun 2015
- Completion
- 30 Nov 2015
- Last update posted
- 21 Apr 2016
- Registered enrollment
- 21
- Registry id
- NCT01828346
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.